Loading
When immunotherapy works, specific immune cell families multiply in the blood within weeks. Tracking that could tell patients early whether to continue.
Peripheral T-cell receptor repertoire dynamics (clonal expansion, clonal replacement and the appearance of tumour-matched clones) have been associated with response in melanoma, lung and bladder cancer, but the analyses are retrospective, use different metrics and different platforms, and have never been locked as a prospective decision rule. Sequencing cost is now low enough for serial monitoring.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Immune-related adverse events (irAEs), No one can predict who responds to immunotherapy, Melanoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, RNA sequencing & expression profiling, Biomarkers are not validated or standardised.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Liquid biopsy (ctDNA), Bladder & urothelial cancer.
Shares Adaptive Biotechnologies, NGS-based MRD (clonoSEQ and molecular MRD), Biomarkers are not validated or standardised, Liquid biopsy (ctDNA).
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised, Melanoma.